Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
561 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.